DOCSLIB.ORG

Loss of a Negative Feedback Loop Between IRF8 and AR Promotes

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Loss of a Negative Feedback Loop Between IRF8 and AR Promotes Author Manuscript Published OnlineFirst on April 27, 2020; DOI: 10.1158/0008-5472.CAN-19-2549 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 1 Loss of a negative feedback loop between IRF8 and AR promotes 2 prostate cancer growth and enzalutamide resistance 3 4 Hongxi Wu1, †, Linjun You1, †, Yan Li1, †, Zhili Zhao1, †, Guangjiang Shi1, Zhen 5 Chen1, Zhuo Wang1, Xianjing Li1, Shijia Du1, Wanli Ye1, Xiaofang Gao1, Jingjing 6 Duan1, Yan Cheng1, Weiyan Tao1, Jinsong Bian4, Jin-Rong Zhou3, Qingyi Zhu2, * & 7 Yong Yang1, * 8 9 1State Key Laboratory of Natural Medicines, China Pharmaceutical University, 10 Nanjing 211198, China 11 2Department of Urology, Jiangsu Province Hospital of Traditional Chinese Medicine, 12 Nanjing 210029, China 13 3Nutrition/Metabolism Laboratory, Department of Surgery/General Surgery, Harvard 14 Medical School, Boston, Massachusetts 15 4Department of Pharmacology, Yong Loo Lin School of Medicine, National University 16 of Singapore, 117597, Singapore 17 18 Footnotes: † They contributed equally to this paper. 19 20 Running title: IRF8 inhibits prostate cancer progress. 21 22 Keywords: Prostate cancer; Castration-resistant prostate cancer; Interferon regulatory 23 factor 8; Enzalutamide resistance; Androgen receptor 24 25 Disclosures of Potential Conflicts of Interest: We declare no conflict of interest. 26 27 Corresponding Author: 28 Prof. Yong Yang, State Key Laboratory of Natural Medicines, China Pharmaceutical 29 University, Nanjing 211198, China. Phone and Fax: 86-025-86185622; E-mail: 30 [email protected] 31 Dr. Qingyi Zhu, Department of Urology, Jiangsu Province Hospital of Traditional 32 Chinese Medicine, Nanjing 210029. Phone and Fax: 86-025-86617141-90506; E-mail: 33 [email protected]. 34 35 36 37 38 39 1 Downloaded from cancerres.aacrjournals.org on September 30, 2021. © 2020 American Association for Cancer Research. Author Manuscript Published OnlineFirst on April 27, 2020; DOI: 10.1158/0008-5472.CAN-19-2549 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 40 Abstract 41 In incurable castration-resistant prostate cancer (CRPC), resistance to the novel 42 androgen receptor (AR) antagonist enzalutamide (ENZ) is driven mainly by AR 43 overexpression. Here we report that the expression of interferon regulatory factor 8 44 (IRF8) is increased in primary prostate cancer (PCa) but decreased in CRPC 45 compared to normal prostate tissue. Decreased expression of IRF8 positively 46 associated with CRPC progression and ENZ resistance. IRF8 interacted with AR and 47 promoted its degradation via activation of the ubiquitin/proteasome systems. 48 Epigenetic knockdown of IRF8 promoted AR-mediated PCa progression and ENZ 49 resistance in vitro and in vivo. Furthermore, IFNα increased expression of IRF8 and 50 improved the efficacy of ENZ in CRPC by targeting the IRF8-AR axis. We also 51 provide preliminary evidence for the efficacy of IFNα with hormonotherapy in a 52 clinical study. Collectively, this study identifies IRF8 both as a tumor suppressor in 53 PCa pathogenesis and a potential alternative therapeutic option to overcome ENZ 54 resistance. 55 56 The statement of significance 57 Findings identify IRF8-mediated AR degradation as a mechanism of resistance to AR 58 targeted therapy, highlighting the therapeutic potential of IFNα in targeting IRF8-AR 59 axis in CRPC. 60 2 Downloaded from cancerres.aacrjournals.org on September 30, 2021. © 2020 American Association for Cancer Research. Author Manuscript Published OnlineFirst on April 27, 2020; DOI: 10.1158/0008-5472.CAN-19-2549 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 61 Introduction 62 Androgen and androgen receptor (AR) signaling pathway play a critical role in the 63 carcinogenesis and progression of prostate cancer (PCa), which is the second leading 64 cause of cancer-related deaths in North America (1). Consequently, androgen 65 depletion therapy (ADT) has been the first-line therapy for primary PCa for decades. 66 Despite the initial efficacy of ADT, regeneration of tumour will occur eventually in 67 almost every patient, leading to alleged castration-resistant prostate cancer (CRPC). 68 AR-targeted therapy is a gold standard therapy for CRPC (2-4). Enzalutamide 69 (ENZ) is approved for the treatment of CRPC patients, based on its ability to block 70 androgen binding to AR in a competitive manner, inhibiting AR nuclear translocation 71 and DNA fixation (5-7). Despite the success of ENZ in improving the overall survival 72 of CRPC patients, inherent or acquired ENZ resistance (ENZR) remains a major 73 clinical challenge (8-10). AR deregulation, including overexpression of AR 74 full-length (ARfl) and AR variants (ARvs), has been identified as a unique factor 75 consistently associated with the progression of PCa to CRPC and ENZR (9); therefore, 76 studying the mechanisms of AR deregulation is critical to improve the efficacy of 77 current treatments. AR undergoes degradation mainly by the ubiquitin/proteasome 78 system, as well as modification of protein stability triggered by ubiquitin-like 79 signaling pathways, such as ISGylation (Interferon stimulated gene) (11,12). AR is a 80 type I interferon (IFN) regulated protein and disruption of interferon system genes 81 plays a novel function in malignant transformation of PCa (12-15). However, the 3 Downloaded from cancerres.aacrjournals.org on September 30, 2021. © 2020 American Association for Cancer Research. Author Manuscript Published OnlineFirst on April 27, 2020; DOI: 10.1158/0008-5472.CAN-19-2549 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 82 mechanism for AR maintaining its stability under the influence of interferon system 83 remains unknown. 84 Activity of the interferon system is mainly regulated by interferon regulatory 85 factor 8 (IRF8), a member of the IRF family (IRF1-9) (16). Loss of IRF8 in immune 86 cells leads to the occurrence of chronic myelogenous leukemia and aberrant 87 methylation of IRF8 gene in nonhemopoietic cells play an increasingly important role 88 in tumorigenesis (17-25). Among all the IRFs, only IRF8 facilitates a protein-protein 89 interactions model by interacts with proteins containing the PEST motif, a region that 90 plays an important role in protein degradation by the proteasome system, including 91 AR degradation (26,27). Emerging evidences suggest that IRF8 may function in the 92 cytosol ubiquitylation system (16,28), but the exact role and the regulation 93 mechanism of IRF8 in cancers, especially in PCa tissues, have not been explored. 94 More importantly, the relationship between IRF8 with AR in PCa and whether IRF8 95 interacts with AR (containing the PEST motif) and functions in the regulation of AR 96 stability are still unknown. 97 The present study provides evidences to support an advantaged role for IRF8 in 98 CRPC and ENZR, and this role of IRF8 is likely mediated through regulating AR 99 stability. We then evaluated the potential of IFNα targeting IRF8 to improve the 100 therapeutic efficacy of hormonotherapy in PCa, suggesting that IFNα combined with 101 ENZ is an attractive therapeutic strategy for CRPC and ENZR. 102 4 Downloaded from cancerres.aacrjournals.org on September 30, 2021. © 2020 American Association for Cancer Research. Author Manuscript Published OnlineFirst on April 27, 2020; DOI: 10.1158/0008-5472.CAN-19-2549 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 103 Materials and Methods 104 Reagents 105 Fetal bovine serum (FBS) and charcoal-stripped, dextran-treated fetal bovine serum 106 (CSS, depleted androgen and any other steroid) were purchased from Biological 107 Industries (Israel). Enzalutamide (MedChemExpress, USA), R1881, 108 Dihydrotestosterone (DHT) (Meilunbio, China), EGF, IGF-1 were commercially 109 obtained (Peprotech, USA). Serial dilutions of all drugs were made using DMSO. 110 111 Cell lines and primary cultures 112 PC-3 cells were cultured in F12 Medium, HEK293T were cultured in DMEM 113 Medium, 22RV1 cells and LNCaP cells were cultured in RPMI-1640 Medium. PC-3, 114 22RV1, LNCaP and HEK293T cells were purchased from were purchased from Cell 115 Bank of the Chinese Academy of Sciences (Shanghai, China), two stable 116 LNCaP-sh-IRF8-Puro (LNCaP-shIRF8) and LNCaP-sh-negative control 117 (LNCaP-shNC)-Puro cells were purchased from GenePharma Technology Co. Ltd. 118 (GenePharma, Shanghai, China). All cells were authenticated by the Short Tandem 119 Repeat DNA profiling (Cobioer, Nanjing, China) and confirmed Mycoplasma free 120 using GMyc-PCR Mycoplasma Test Kit (YeSen; Shanghai, China, 40601ES10) after 121 last experiment, and used within 15 cell passages after thawing. All cell lines were 122 cultured in medium supplemented with 10% fetal bovine serum (Sigma), 1% 123 Penicillin-Streptomycin (Gibico), 5% CO2, 37 °C. 5 Downloaded from cancerres.aacrjournals.org on September 30, 2021. © 2020 American Association for Cancer Research. Author Manuscript Published OnlineFirst on April 27, 2020; DOI: 10.1158/0008-5472.CAN-19-2549 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 124 Plasmids, siRNA and DNA transient transfections 125 Plasmids including pcDNA3 (Vector), pcDNA3-hIRF8 (IRF8), pcDNA3-hAR (AR), 126 containing the whole CDS domains were constructed by Genscript (Nanjing, China); 127 double luciferase reporter plasmid pEZX-FR03-hIRF8-luc, carrying the IRF8 128 promoter (-1106-+166bp), was constructed by FulenGen (Guangzhou, China); 129 3xFlag-Ub plasmid was generously provided by Dr. Guo-qiang Xu (Soochow 130 University, China). For transient transfections, cells were seeded into six-well plates 131 at 150,000 cells per well and transfected with IRF8 or AR expression vectors using 132 empty vector (pvector) as control. The total plasmid DNA was adjusted to the same 133 with empty vector. 134 siRNA and shRNA targeting IRF8 are as follows: siNC (shNC): TTC TCC GAA 135 CGT GTC ACG TTT C; siRNA1# (shIRF8A): GCA GTT CTA TAA CAG CCA GGG; 136 siRNA2# (shIRF8B): GGG AAG AGT TTC CGG ATA TGG.
Load more

Recommended publications
  • The Master Neural Transcription Factor BRN2 Is an Androgen Receptor–Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer
    Published OnlineFirst October 26, 2016; DOI: 10.1158/2159-8290.CD-15-1263 RESEARCH ARTICLE The Master Neural Transcription Factor BRN2 Is an Androgen Receptor–Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer Jennifer L. Bishop1, Daksh Thaper1,2, Sepideh Vahid1,2, Alastair Davies1, Kirsi Ketola1, Hidetoshi Kuruma1, Randy Jama1, Ka Mun Nip1,2, Arkhjamil Angeles1, Fraser Johnson1, Alexander W. Wyatt1,2, Ladan Fazli1,2, Martin E. Gleave1,2, Dong Lin1, Mark A. Rubin3, Colin C. Collins1,2, Yuzhuo Wang1,2, Himisha Beltran3, and Amina Zoubeidi1,2 ABSTRACT Mechanisms controlling the emergence of lethal neuroendocrine prostate cancer (NEPC), especially those that are consequences of treatment-induced suppression of the androgen receptor (AR), remain elusive. Using a unique model of AR pathway inhibitor–resistant prostate cancer, we identified AR-dependent control of the neural transcription factor BRN2 (encoded by POU3F2) as a major driver of NEPC and aggressive tumor growth, both in vitro and in vivo. Mecha- nistic studies showed that AR directly suppresses BRN2 transcription, which is required for NEPC, and BRN2-dependent regulation of the NEPC marker SOX2. Underscoring its inverse correlation with clas- sic AR activity in clinical samples, BRN2 expression was highest in NEPC tumors and was significantly increased in castration-resistant prostate cancer compared with adenocarcinoma, especially in patients with low serum PSA. These data reveal a novel mechanism of AR-dependent control of NEPC and suggest that targeting BRN2 is a strategy to treat or prevent neuroendocrine differentiation in prostate tumors. SIGNIFICANCE: Understanding the contribution of the AR to the emergence of highly lethal, drug- resistant NEPC is critical for better implementation of current standard-of-care therapies and novel drug design.
    [Show full text]
  • Quantitative Modelling Explains Distinct STAT1 and STAT3
    bioRxiv preprint doi: https://doi.org/10.1101/425868; this version posted September 24, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Title Quantitative modelling explains distinct STAT1 and STAT3 activation dynamics in response to both IFNγ and IL-10 stimuli and predicts emergence of reciprocal signalling at the level of single cells. 1,2, 3 1 1 1 1 1 2 Sarma U , Maitreye M , Bhadange S , Nair A , Srivastava A , Saha B , Mukherjee D . 1: National Centre for Cell Science, NCCS Complex, Ganeshkhind, SP Pune University Campus, Pune 411007, India. 2 : Corresponding author. [email protected] , [email protected] 3: Present address. Labs, Persistent Systems Limited, Pingala – Aryabhata, Erandwane, Pune, 411004 India. bioRxiv preprint doi: https://doi.org/10.1101/425868; this version posted September 24, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Abstract Cells use IFNγ-STAT1 and IL-10-STAT3 pathways primarily to elicit pro and anti-inflammatory responses, respectively. However, activation of STAT1 by IL-10 and STAT3 by IFNγ is also observed. The regulatory mechanisms controlling the amplitude and dynamics of both the STATs in response to these functionally opposing stimuli remains less understood. Here, our experiments at cell population level show distinct early signalling dynamics of both STAT1 and STAT3(S/1/3) in responses to IFNγ and IL-10 stimulation.
    [Show full text]
  • A Molecular Switch from STAT2-IRF9 to ISGF3 Underlies Interferon-Induced Gene Transcription
    ARTICLE https://doi.org/10.1038/s41467-019-10970-y OPEN A molecular switch from STAT2-IRF9 to ISGF3 underlies interferon-induced gene transcription Ekaterini Platanitis 1, Duygu Demiroz1,5, Anja Schneller1,5, Katrin Fischer1, Christophe Capelle1, Markus Hartl 1, Thomas Gossenreiter 1, Mathias Müller2, Maria Novatchkova3,4 & Thomas Decker 1 Cells maintain the balance between homeostasis and inflammation by adapting and inte- grating the activity of intracellular signaling cascades, including the JAK-STAT pathway. Our 1234567890():,; understanding of how a tailored switch from homeostasis to a strong receptor-dependent response is coordinated remains limited. Here, we use an integrated transcriptomic and proteomic approach to analyze transcription-factor binding, gene expression and in vivo proximity-dependent labelling of proteins in living cells under homeostatic and interferon (IFN)-induced conditions. We show that interferons (IFN) switch murine macrophages from resting-state to induced gene expression by alternating subunits of transcription factor ISGF3. Whereas preformed STAT2-IRF9 complexes control basal expression of IFN-induced genes (ISG), both type I IFN and IFN-γ cause promoter binding of a complete ISGF3 complex containing STAT1, STAT2 and IRF9. In contrast to the dogmatic view of ISGF3 formation in the cytoplasm, our results suggest a model wherein the assembly of the ISGF3 complex occurs on DNA. 1 Max Perutz Labs (MPL), University of Vienna, Vienna 1030, Austria. 2 Institute of Animal Breeding and Genetics, University of Veterinary Medicine Vienna, Vienna 1210, Austria. 3 Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna 1030, Austria. 4 Research Institute of Molecular Pathology (IMP), Vienna Biocenter (VBC), Vienna 1030, Austria.
    [Show full text]
  • IRF8 Regulates Gram-Negative Bacteria–Mediated NLRP3 Inflammasome Activation and Cell Death
    IRF8 Regulates Gram-Negative Bacteria− Mediated NLRP3 Inflammasome Activation and Cell Death This information is current as Rajendra Karki, Ein Lee, Bhesh R. Sharma, Balaji Banoth of September 25, 2021. and Thirumala-Devi Kanneganti J Immunol published online 23 March 2020 http://www.jimmunol.org/content/early/2020/03/20/jimmun ol.1901508 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2020/03/20/jimmunol.190150 Material 8.DCSupplemental http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 25, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2020 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published March 23, 2020, doi:10.4049/jimmunol.1901508 The Journal of Immunology IRF8 Regulates Gram-Negative Bacteria–Mediated NLRP3 Inflammasome Activation and Cell Death Rajendra Karki,*,1 Ein Lee,*,†,1 Bhesh R. Sharma,*,1 Balaji Banoth,* and Thirumala-Devi Kanneganti* Inflammasomes are intracellular signaling complexes that are assembled in response to a variety of pathogenic or physiologic stimuli to initiate inflammatory responses.
    [Show full text]
  • Reduced Expression of IL-12 Receptor B2 and IL-18 Receptor a Genes in Natural Killer Cells and Macrophages Derived from B6-Mi/Mi Mice
    Laboratory Investigation (2005) 85, 146–153 & 2005 USCAP, Inc All rights reserved 0023-6837/05 $30.00 www.laboratoryinvestigation.org Reduced expression of IL-12 receptor b2 and IL-18 receptor a genes in natural killer cells and macrophages derived from B6-mi/mi mice Tatsuki R Kataoka1,2, Nobuyasu Komazawa3, Keisuke Oboki1, Eiichi Morii1 and Toru Nakano1,4 1Department of Pathology, Medical School/Graduate School of Frontier Bioscience, Osaka University, Osaka, Japan; 2Department of Pathology, Osaka Medical Center for Cancer and Cardiovascular Disease, Osaka, Japan; 3Department of Social and Environmental Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan and 4Department of Molecular Cell Biology, Research Institute for Microbial Disease, Osaka University, Osaka, Japan The mi transcriptional factor (MITF) is a basic helix–loop–helix leucine zipper-type transcriptional factor. The mi mutant allele encodes an abnormal MITF, in which one out of four consecutive arginines is deleted in the basic domain. The VGA-9-tg (tg) allele is another mutant allele and considered to be a null mutant allele. C57BL/6 (B6)- mi/mi mice showed abnormal phenotypes of natural killer (NK) cells and macrophages, whereas B6-tg/tg mice did not. The expression levels of the genes for the interleukin-12 receptor (IL-12R) b2 and IL-18Ra were reduced in both the NK cells and macrophages of B6-mi/mi mice, while the expression levels of the corresponding genes in B6-tg/tg mice were unaffected. The B6-mi/mi NK cells and B6-mi/mi macrophages showed impaired responses to stimulation with IL-12, IL-18, and IL-12 plus IL-18 stimulation.
    [Show full text]
  • Partner-Regulated Interaction of IFN Regulatory Factor 8 with Chromatin Visualized in Live Macrophages
    Partner-regulated interaction of IFN regulatory factor 8 with chromatin visualized in live macrophages Leopoldo Laricchia-Robbio*, Tomohiko Tamura*, Tatiana Karpova†, Brian L. Sprague†, James G. McNally†, and Keiko Ozato*‡ *Laboratory of Molecular Growth Regulation, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892-2753; and †Laboratory of Receptor Biology and Gene Expression, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-5055 Edited by Laurie H. Glimcher, Harvard School of Public Health, Boston, MA, and approved August 18, 2005 (received for review May 17, 2005) IFN regulatory factor (IRF) 8 is a transcription factor that directs protein–protein interactions on fluorescence recovery have not macrophage differentiation. By fluorescence recovery after pho- been extensively studied. Moreover, many FRAP studies so far tobleaching, we visualized the movement of IRF8-GFP in differen- reported are qualitative, lacking quantitative insight into the tiating macrophages. Recovery data fitted to mathematical models chromatin-binding events. More recent efforts to fit FRAP data revealed two binding states for IRF8. The majority of IRF8 was to mathematical models begin to provide a clearer knowledge on highly mobile and transiently interacted with chromatin, whereas the property of FRAP mobility (16, 17). a small fraction of IRF8 bound to chromatin more stably. IRF8 IRF8, a member of the IFN regulatory factor (IRF) family, is mutants that did not stimulate macrophage differentiation a key factor that guides the development of macrophages (18). showed a faster recovery, revealing little interaction with chro- We previously established an in vitro model system where matin. A macrophage activation signal by IFN-␥͞LPS led to a global IRF8Ϫ/Ϫ myeloid progenitor cells called Tot2 differentiate into slowdown of IRF8 movement, leading to increased chromatin macrophages upon IRF8 introduction (19).
    [Show full text]
  • STAT1 Signalling Predicts Response to Chemotherapy in Oestrogen Receptor-Negative Breast Cancer
    FULL PAPER British Journal of Cancer (2016) 114, 177–187 | doi: 10.1038/bjc.2015.398 Keywords: STAT1; ER-negative breast cancer; IFN; chemotherapy; predictive signature Activation of IFN/STAT1 signalling predicts response to chemotherapy in oestrogen receptor-negative breast cancer Marie-Emmanuelle Legrier1, Ivan Bie` che2, Julie Gaston1, Arnaud Beurdeley1, Vanessa Yvonnet1, Olivier De´as1, Aure´ lie Thuleau3, Sophie Chaˆ teau-Joubert4, Jean-Luc Servely4,5, Sophie Vacher2, Myriam Lassalle1, Ste´ phane Depil6, Gordon C Tucker6, Jean-Jacques Fontaine4, Marie-France Poupon1, Sergio Roman-Roman3, Jean-Gabriel Judde1, Didier Decaudin3,7, Stefano Cairo*,1,8,9 and Elisabetta Marangoni*,3,9 1XenTech, 4 rue Pierre Fontaine, Evry 91000, France; 2Genetics Department, Hospital, Institut Curie, 26 rue d’Ulm, Paris 75005, France; 3Translational Research Department, Institut Curie, 26 rue d’Ulm, Paris 75005, France; 4Department of Pathology, Veterinary School of Alfort, Maisons-Alfort 94704, France; 5INRA, Phase Department, Nouzilly, France; 6Institut de Recherches Servier, PIT Oncology, Croissy-sur-Seine 78290, France; 7Medical Oncology Department, Institut Curie, 26 rue d’Ulm, Paris 75005, France and 8University of Ferrara, LTTA Centre, Department of Morphology, Surgery and Experimental Medicine, Ferrara, Italy Background: Oestrogen receptor-negative (ER À ) breast cancer is intrinsically sensitive to chemotherapy. However, tumour response is often incomplete, and relapse occurs with high frequency. The aim of this work was to analyse the molecular characteristics of residual tumours and early response to chemotherapy in patient-derived xenografts (PDXs) of breast cancer. Methods: Gene and protein expression profiles were analysed in a panel of ER À breast cancer PDXs before and after chemotherapy treatment.
    [Show full text]
  • An Immunoevasive Strategy Through Clinically-Relevant Pan-Cancer Genomic and Transcriptomic Alterations of JAK-STAT Signaling Components
    bioRxiv preprint doi: https://doi.org/10.1101/576645; this version posted March 14, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. An immunoevasive strategy through clinically-relevant pan-cancer genomic and transcriptomic alterations of JAK-STAT signaling components Wai Hoong Chang1 and Alvina G. Lai1, 1Nuffield Department of Medicine, University of Oxford, Old Road Campus, Oxford, OX3 7FZ, United Kingdom Since its discovery almost three decades ago, the Janus ki- Although cytokines are responsible for inflammation in nase (JAK)-signal transducer and activator of transcription cancer, spontaneous eradication of tumors by endoge- (STAT) pathway has paved the road for understanding inflam- nous immune processes rarely occurs. Moreover, the matory and immunity processes related to a wide range of hu- dynamic interaction between tumor cells and host immu- man pathologies including cancer. Several studies have demon- nity shields tumors from immunological ablation, which strated the importance of JAK-STAT pathway components in overall limits the efficacy of immunotherapy in the clinic. regulating tumor initiation and metastatic progression, yet, the extent of how genetic alterations influence patient outcome is far from being understood. Focusing on 133 genes involved in Cytokines can be pro- or anti-inflammatory and are inter- JAK-STAT signaling, we found that copy number alterations dependent on each other’s function to maintain immune underpin transcriptional dysregulation that differs within and homeostasis(3).
    [Show full text]
  • Transcription Factor IRF8 Directs a Silencing Programme for TH17 Cell Differentiation
    ARTICLE Received 17 Aug 2010 | Accepted 13 Apr 2011 | Published 17 May 2011 DOI: 10.1038/ncomms1311 Transcription factor IRF8 directs a silencing programme for TH17 cell differentiation Xinshou Ouyang1, Ruihua Zhang1, Jianjun Yang1, Qingshan Li1, Lihui Qin2, Chen Zhu3, Jianguo Liu4, Huan Ning4, Min Sun Shin5, Monica Gupta6, Chen-Feng Qi5, John Cijiang He1, Sergio A. Lira1, Herbert C. Morse III5, Keiko Ozato6, Lloyd Mayer1 & Huabao Xiong1 TH17 cells are recognized as a unique subset of T helper cells that have critical roles in the pathogenesis of autoimmunity and tissue inflammation. Although OR Rγt is necessary for the generation of TH17 cells, the molecular mechanisms underlying the functional diversity of TH17 cells are not fully understood. Here we show that a member of interferon regulatory factor (IRF) family of transcription factors, IRF8, has a critical role in silencing TH17-cell differentiation. Mice with a conventional knockout, as well as a T cell-specific deletion, of the Irf8 gene exhibited more efficient TH17 cells. Indeed, studies of an experimental model of colitis showed that IRF8 deficiency resulted in more severe inflammation with an enhanced TH17 phenotype. IRF8 was induced steadily and inhibited TH17-cell differentiation during TH17 lineage commitment at least in part through its physical interaction with RORγt. These findings define IRF8 as a novel intrinsic transcriptional inhibitor of TH17-cell differentiation. 1 Immunology Institute, Department of Medicine, Mount Sinai School of Medicine, 1 Gustave L. Levy Place, New York, New York 10029, USA. 2 Department of Pathology, Mount Sinai School of Medicine, New York, New York 10029, USA.
    [Show full text]
  • Estrogen Receptors and Ubiquitin Proteasome System: Mutual Regulation
    biomolecules Review Estrogen Receptors and Ubiquitin Proteasome System: Mutual Regulation Irina V. Kondakova 1 , Elena E. Shashova 1, Evgenia A. Sidenko 1, Tatiana M. Astakhova 2, Liudmila A. Zakharova 2 and Natalia P. Sharova 2,* 1 Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, 5 Kooperativny Street, 634009 Tomsk, Russia; [email protected] (I.V.K.); [email protected] (E.E.S.); [email protected] (E.A.S.) 2 Koltzov Institute of Developmental Biology, Russian Academy of Sciences, 26 Vavilov Street, 119334 Moscow, Russia; [email protected] (T.M.A.); [email protected] (L.A.Z.) * Correspondence: [email protected]; Tel.: +7-499-135-7674; Fax: +7-499-135-3322 Received: 16 February 2020; Accepted: 25 March 2020; Published: 26 March 2020 Abstract: This review provides information on the structure of estrogen receptors (ERs), their localization and functions in mammalian cells. Additionally, the structure of proteasomes and mechanisms of protein ubiquitination and cleavage are described. According to the modern concept, the ubiquitin proteasome system (UPS) is involved in the regulation of the activity of ERs in several ways. First, UPS performs the ubiquitination of ERs with a change in their functional activity. Second, UPS degrades ERs and their transcriptional regulators. Third, UPS affects the expression of ER genes. In addition, the opportunity of the regulation of proteasome functioning by ERs—in particular, the expression of immune proteasomes—is discussed. Understanding the complex mechanisms underlying the regulation of ERs and proteasomes has great prospects for the development of new therapeutic agents that can make a significant contribution to the treatment of diseases associated with the impaired function of these biomolecules.
    [Show full text]
  • Vs. BCR-ABL-Positive Cells to Interferon Alpha
    Schubert et al. Journal of Hematology & Oncology (2019) 12:36 https://doi.org/10.1186/s13045-019-0722-9 RESEARCH Open Access Differential roles of STAT1 and STAT2 in the sensitivity of JAK2V617F- vs. BCR-ABL- positive cells to interferon alpha Claudia Schubert1, Manuel Allhoff2, Stefan Tillmann1, Tiago Maié2, Ivan G. Costa2, Daniel B. Lipka3, Mirle Schemionek1, Kristina Feldberg1, Julian Baumeister1, Tim H. Brümmendorf1, Nicolas Chatain1† and Steffen Koschmieder1*† Abstract Background: Interferon alpha (IFNa) monotherapy is recommended as the standard therapy in polycythemia vera (PV) but not in chronic myeloid leukemia (CML). Here, we investigated the mechanisms of IFNa efficacy in JAK2V617F- vs. BCR-ABL-positive cells. Methods: Gene expression microarrays and RT-qPCR of PV vs. CML patient PBMCs and CD34+ cells and of the murine cell line 32D expressing JAK2V617F or BCR-ABL were used to analyze and compare interferon-stimulated gene (ISG) expression. Furthermore, using CRISPR/Cas9n technology, targeted disruption of STAT1 or STAT2, respectively, was performed in 32D-BCR-ABL and 32D-JAK2V617F cells to evaluate the role of these transcription factors for IFNa efficacy. The knockout cell lines were reconstituted with STAT1, STAT2, STAT1Y701F, or STAT2Y689F to analyze the importance of wild-type and phosphomutant STATs for the IFNa response. ChIP-seq and ChIP were performed to correlate histone marks with ISG expression. Results: Microarray analysis and RT-qPCR revealed significant upregulation of ISGs in 32D-JAK2V617F but downregulation in 32D-BCR-ABL cells, and these effects were reversed by tyrosine kinase inhibitor (TKI) treatment. Similar expression patterns were confirmed in human cell lines, primary PV and CML patient PBMCs and CD34+ cells, demonstrating that these effects are operational in patients.
    [Show full text]
  • A Dual Cis-Regulatory Code Links IRF8 to Constitutive and Inducible Gene Expression in Macrophages
    Downloaded from genesdev.cshlp.org on October 1, 2021 - Published by Cold Spring Harbor Laboratory Press A dual cis-regulatory code links IRF8 to constitutive and inducible gene expression in macrophages Alessandra Mancino,1,3 Alberto Termanini,1,3 Iros Barozzi,1 Serena Ghisletti,1 Renato Ostuni,1 Elena Prosperini,1 Keiko Ozato,2 and Gioacchino Natoli1 1Department of Experimental Oncology, European Institute of Oncology (IEO), 20139 Milan, Italy; 2Laboratory of Molecular Growth Regulation, Genomics of Differentiation Program, National Institute of Child Health and Human Development (NICHD), National Institutes of Health, Bethesda, Maryland 20892, USA The transcription factor (TF) interferon regulatory factor 8 (IRF8) controls both developmental and inflammatory stimulus-inducible genes in macrophages, but the mechanisms underlying these two different functions are largely unknown. One possibility is that these different roles are linked to the ability of IRF8 to bind alternative DNA sequences. We found that IRF8 is recruited to distinct sets of DNA consensus sequences before and after lipopolysaccharide (LPS) stimulation. In resting cells, IRF8 was mainly bound to composite sites together with the master regulator of myeloid development PU.1. Basal IRF8–PU.1 binding maintained the expression of a broad panel of genes essential for macrophage functions (such as microbial recognition and response to purines) and contributed to basal expression of many LPS-inducible genes. After LPS stimulation, increased expression of IRF8, other IRFs, and AP-1 family TFs enabled IRF8 binding to thousands of additional regions containing low-affinity multimerized IRF sites and composite IRF–AP-1 sites, which were not premarked by PU.1 and did not contribute to the basal IRF8 cistrome.
    [Show full text]